| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.8 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | XMD11-85h | GDSC1000 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.9 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.9 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.9 |